Document:

*****
        Confidential material redacted and filed separately with the
        Commission.

    

     

    

      Confidential
        Treatment Requested. Confidential portions of this document have been redacted
        and separately filed with the Commission.

      

      Date:
        August 31, 1995

      

      
        	
                TO:
                  

              	
                Yeda
                  Research and Development Company
                  Ltd.

              

      

      P.O.
        Box
        95 

      Rehovot
        76100

      ATTENTION:
        MR. *****

      

      Dear
        Sirs,

      

      Re:
        Amendment
        of Research and License Agreement

      

      This
        letter, when counter-signed by an authorized representative of Yeda Research
        and
        Development Ltd. (“Yeda”) will constitute an agreement between Yeda and XTL
        Biopharmaceuticals Ltd. (formerly named Xenograft Technologies Ltd.-“XTL”) to
        extend the period of research under the Research and License Agreement entered
        into by Yeda and XTL on April 7, 1993 (the “R&L Agreement”) and otherwise to
        amend the R&L Agreement, as hereinafter provided (unless otherwise herein
        defined, all capitalized terms appearing herein having the meanings ascribed
        to
        them in the R&L Agreement):

      

      1.
        General

      

      
        	1.1.	
                XTL
                  has advised Yeda that XTL *****.

              

      

      

      
        	
                1.2.

              	
                XTL
                  wishes to modify and diversify the rates of royalties due to Yeda
                  under
                  the R&L Agreement as hereinafter provided and Yeda agrees
                  thereto.

              

      

      

      
        	
                1.3.

              	
                XTL
                  wishes to receive, and Yeda is willing to grant to XTL, a grace
                  period
                  prior to commencement of certain royalty payments under the R&L
                  Agreement, as hereinafter provided.

              

      

      

      2.
        Royalties

      

      
        	2.1.	
                Royalty
                  Rates

              

      

      

      Instead
        of the royalties payable as specified in Clause 7(d)(ii) of the R&L
        Agreement, and subject to Section 2.2 below, the royalties payable to Yeda
        by
        XTL in consideration of the Licence granted under the R&L Agreement, shall
        be as follows:

      

      
        	
                2.1.1.

              	
                *****
                  percent) of Net Sales (as hereinafter defined) from sales by XTL
                  of
                  pharmaceutical products developed and/or made under and/or using
                  the
                  Licensed Patents and/or the Licensed Technology. “Net Sales” as used
                  herein shall have the meaning ascribed to the term in the R&L
                  Agreement, references therein to “the Products” being read as references
                  to the pharmaceutical products referred to
                  hereinbefore.

              

      

      

      
        
           

        

        
          1

          
            

          

        

        
          
            *****
              Confidential material redacted and filed separately with the
              Commission.

          

        

         

      

      
        	
                2.1.2.

              	
                *****
                  percent) of all amounts received by XTL from third parties (except
                  the
                  amounts governed by Section 2.1.4 below) under or pursuant to agreements
                  allowing *****,
                  provided
                  that if XTL shall be obliged to pay a royalty of more than *****
                  per cent) on any such amounts to a third party pursuant to a bona
                  fide
                  arms-length agreement with such third party (“a third party royalty”),
                  then the rate of royalty payable to Yeda pursuant to this Section
                  2.1.2 on
                  amounts subject to a third party royalty shall be reduced by the
                  percentage - up to a maximum *****
                  per cent) - by which the third party royalty rate exceeds *****
                  per cent), so that if,
                  for example, the third party royalty rate is *****
                  per cent) the rate of royalty payable to Yeda pursuant to this
                  Section
                  2.1.2 shall be *****
                  per cent), and if, as a further example, the third party royalty
                  rate is
                  *****
                  per cent), the rate of royalty payable to Yeda pursuant to this
                  Section
                  2.1.2 shall be reduced by *****
                  per cent).

              

      

      

      
        	
                2.1.3.

              	
                *****
                  percent) of all amounts received by XTL from a third party payable
                  *****
                  the Licensed Patents and/or the Licensed
                  Technology.

              

      

      

      
        	
                2.1.4.

              	
                *****
                  percent) of all amounts received by XTL under or pursuant to agreements
                  with third parties *****
                  using the Licensed Patents and/or the Licensed
                  Technology.

              

      

      

      
        	
                2.1.5.
                  

              	
                *****
                  percent) of all amounts received by XTL as a result of *****,
                  other than those specified in Sections 2.1.1, 2.1.2, 2.1.3 or 2.1.4
                  above.
                  Where the amounts received by XTL are the result of activities
                  not
                  involving the grant of sublicences to third parties (“Direct Activities”)
                  and are amounts received in a transaction other than at arms length,
                  the
                  royalty due to Yeda shall be calculated on the amount that would
                  have been
                  received by XTL in a transaction at arms
                  length.

              

      

      

      
        	
                2.1.6.

              	
                For
                  the avoidance of doubt, it is expressly stated that royalties shall
                  not be
                  due pursuant to Sections 2.1.2, 2.1.4 or 2.1.5 above on *****.

              

      

      

      
        	
                2.1.7.
                  

              	
                For
                  the avoidance of doubt, it is expressly stated, that nothing in
                  this
                  Section 2.1 above or elsewhere in this letter shall be deemed to
                  derogate
                  from the provisions of Clause 7(c) of the R&L Agreement governing the
                  grant of sublicences.

              

      

       

      
        	
                2.2.
                  

              	
                Commencement
                  of Payment of Royalties

              

      

      

      Royalties
        due under the R&L Agreement (as herein amended) shall become payable as
        follows:

      

      
        	2.2.1.	
                XTL's
                  obligation to pay royalties to Yeda pursuant to Sections 2.1.1,
                  2.1.2 or
                  2.1.5 above, shall
                  relate only to amounts received by and/or due to XTL on or after
                  the “Due
                  Date” (as hereinafter defined). The “Due Date” means the earlier of the
                  following dates: (a) the date of expiry of the period *****,
                  and (b) the date on which the aggregate amount received by *****.

              

      

      

      
        	
                2.2.2.

              	
                XTL’s
                  obligation to pay royalties to Yeda pursuant to Section 2.1.3 above
                  shall
                  apply to all amounts subject to royalty under that Section whenever
                  received, provided that actual payment of royalties due to Yeda
                  pursuant
                  to that Section on amounts received by XTL before the Due Date
                  shall be
                  due and made within 30 days of the Due
                  Date.

              

      

      

      
        
           

        

        
          2

          
            

          

        

        
          
            *****
              Confidential material redacted and filed separately with the
              Commission.

          

        

         

      

      
        	
                2.2.3.

              	
                Subject
                  to the provisions
                  of this Section 2.2 above, the provisions of Clause 7(d)(iii) of
                  the
                  R&L Agreement shall apply, mutatis mufandis, to the royalties payable
                  to Yeda pursuant to Section 2.1 above, references to “Net Sales” in the
                  said Clause 7(d)(iii) being deemed references to “Net Sales” as defined in
                  Section 2.1.1 above for the purpose of that Section and to amounts
                  received by XTL from Direct Activities (as defined in Section 2.1.5
                  above)
                  and references to “Sublicensing Receipts” in Clause 7(d)(iii) being deemed
                  references to amounts subject to royalty payment to Yeda pursuant
                  to
                  Sections 2.1.2, 2.1.3, 2.1.4 or 2.1.5 above (not being amounts
                  resulting
                  from Direct Activities (as defined in Section 2.1.5
                  above)).

              

      

      

      
        	
                2.2.4.

              	
                For
                  the avoidance of doubt, it is expressly stated that there shall
                  be no
                  grace period of any kind regarding payment of royalties pursuant
                  to
                  Section 2.1.4 above and they shall be paid on the periodic basis
                  specified
                  in Clause 7(d)(iii) of the R&L
                  Agreement.

              

      

      

      
        	
                2.3.
                  

              	
                For
                  the avoidance of doubt, it is expressly stated that the periods
                  during
                  which royalties shall be payable under the R&L Agreement shall be as
                  follows:

              

      

      

      
        	
                2.3.1.
                  

              	
                Payment
                  of royalties pursuant to Section 2.1.1 shall commence as provided
                  in
                  Section 2.2 and shall continue with respect to sales of any pharmaceutical
                  product as follows:

              

      

      

      
        	 	
                (aa)
                  

              	
                if
                  the product sold is made and/or sold in a country where a Licensed
                  Patent
                  or Patents issue including claims covering, in whole or in part,
                  such
                  product or the manufacture thereof-then, (i) *****;

              

      

      

      
        	 	
                (bb)
                  

              	
                on
                  sales of a product made and sold in any other country, *****.

              

      

      

      
        	
                2.3.2.

              	
                Payment
                  of royalties pursuant to Section 2.1.2 shall commence as provided
                  in
                  Section 2.2 and shall continue as
                  follows:

              

      

      

      
        	
              	(aa)	
                payment
                  of royalties on amounts paid to XTL and attributable to activities
                  of the
                  paying third parry under a Licensed Patent or Patents in a particular
                  country shall continue *****;

              

      

      

      
        	
              	(bb)	
                payment
                  of royalties on amounts paid to XTL and attributable to activities
                  of the
                  paying third party in a particular country in which there is no
                  Licensed
                  Patent *****;

              

      

      

      
        	
              	(cc)	
                payment
                  of royalties on amounts paid to XTL and not attributable to the
                  paying
                  third party's activities in any particular country, shall continue
                  until
                  *****.

              

      

      

      
        	
                2.3.3.

              	
                Payment
                  of royalties pursuant to Section 2.1.3 shall commence as provided
                  in
                  Section 2.2 and shall continue as
                  follows:

              

      

      

      
        	 	
                (aa)
                  

              	
                payment
                  of royalties on amounts paid to XTL and attributable to activities
                  of XTL
                  or of the paying third party under a Licensed Patent or Patents
                  in a
                  particular country shall continue *****,

              

      

      

      
        
           

        

        
          3

          
            

          

        

        
          
            *****
              Confidential material redacted and filed separately with the
              Commission.

          

        

         

      

      
        	 	
                (bb)
                  

              	
                payment
                  of royalties on amounts paid to XTL and attributable to activities
                  of XTL
                  or the paying third party in a particular country in which there
                  is no
                  Licensed Patent *****;

              

      

      

      
        	 	
                (cc)
                  

              	
                payment
                  of royalties on amounts paid to XTL and not attributable to XTL's
                  or the
                  third party's activities in any particular country shall continue
                  until
                  *****.

              

      

      

      
        	
                2.3.4.

              	
                Payment
                  of royalties pursuant to Section 2.1.4 shall commence as provided
                  in
                  Section 2.2 and shall continue as
                  follows:

              

      

      

      
        	
              	(aa)	
                payment
                  of royalties on amounts paid to XTL and attributable to activities
                  of the
                  paying third party under a Licensed Patent or Patents in a particular
                  country shall continue *****;

              

      

      

      
        	
              	(bb)	
                payment
                  of royalties on amounts paid to XTL and attributable to activities
                  of the
                  paying third party in a country in which *****;

              

      

      

      
        	 	
                (cc)
                  

              	
                payment
                  of royalties on amounts paid to XTL and not attributable to the
                  third
                  party's activities in any particular country shall continue, until
                  *****.

              

      

      

      
        	
                2.3.5.

              	
                Payment
                  of royalties pursuant to Section 2.1.5 shall commence as provided
                  in
                  Section 2.2 and shall continue as
                  follows:

              

      

      

      
        	
                (A)

              	
                where
                  the royalties are on
                  amounts
                  received by XTL on any Direct Activity, the duty to pay royalties
                  shall
                  continue:

              

      

       

      
        	 	
                (aa)
                  

              	
                if
                  the activity or any part thereof is carried out in any country
                  under a
                  Licensed Patent or Patents-then, *****;

              

      

      

      
        	 	
                (bb)
                  

              	
                if
                  the activity is carried out in any other country, *****;

              

      

      

      
        	
                (B)

              	
                Where
                  the royalties are due on amounts received by XTL on activities
                  not being a
                  Direct Activity, the duty to pay royalties shall continue as
                  follows::

              

      

      

      
        	 	
                (aa)
                  

              	
                payment
                  of royalties on amounts paid to XTL and attributable to activities
                  of the
                  paying third party under a Licensed Patent or Patents in a particular
                  country shall continue *****;

              

      

      

      
        	 	
                (bb)
                  

              	
                payment
                  of royalties on amounts paid to XTL and attributable to activities
                  of the
                  paying third party in a particular country in which there is no
                  Licensed
                  Patent shall continue *****;

              

      

      

      
        	 	
                (cc)
                  

              	
                payment
                  of royalties on amounts paid to XTL and not attributable to the
                  third
                  party's activities in any particular country shall continue, *****.

              

      

      

      
        	
                2.4.

              	
                The
                  “relevant grace period” for the purpose of any of subsections 2.3.1, 2.3.2
                  and 2.3.5 above, shall mean the period by which commencement of
                  payment of
                  royalties due under subsections 2.1.1, 2.1.2 and 2.1.5, respectively,
                  has
                  been delayed, pursuant to Section 2.2
                  above.

              

      

      

      
        
           

        

        
          4

          
            

          

        

        
          
            *****
              Confidential material redacted and filed separately with the
              Commission.

          

        

         

      

      
        	
                2.5.

              	
                The
                  License granted under the R&L Agreement shall remain in force (if not
                  previously terminated according to the provisions of the R&L Agreement
                  (as amended hereby)) for the purpose of each of the activities
                  specified
                  in Sections 2.1.1, 2.1.2, 2.1.3, 2.1.4 and 2.1.5, as long as there
                  is a
                  duty to pay royalties in respect of such activity, as provided
                  in Section
                  2.3 above. Clause 7(b)(iii) of the R&L Agreement is replaced by the
                  provisions of this Section 2.5
                  above.

              

      

      

      
        	
                3.

              	
                Payments
                  for Sponsored R&D

              

      

      

      
        	
                3.1.

              	
                Subject
                  to the amendments contained herein, the period of research which
                  XTL is
                  obliged to fund under the R&L Agreement is hereby extended by 1 (one)
                  year and shall continue until August 31, 1996 (the “Extension
                  Period”).

              

      

      

      
        	
                3.2.

              	
                XTL
                  shall pay Yeda an
                  aggregate amount in New Israel Sheqels equal (at the representative
                  rate
                  of exchange in force on the date of payment) to *****
                  (plus VAT against VAT invoice) in consideration of Yeda’s undertaking to
                  procure the performance (under the supervision of *****)
                  of research in the Extension Period in accordance with the Research
                  Plan
                  and the Budget attached hereto as Appendices “A” and “B”, respectively, as
                  follows:

              

      

      

      
        	
                3.2.1.

              	
                An
                  amount in New Israel Sheqels equal (at the representative rate
                  of exchange
                  in force on the date of payment) to *****
                  (plus VAT against VAT invoice) on March 31,
                  1996;

              

      

      

      
        	
                3.2.2.

              	
                An
                  amount in New Israel Sheqels equal to *****
                  (plus VAT against VAT invoice) on each of May 15, 1996 and July
                  31,
                  1996.

              

      

      

      
        	
                3.3.

              	
                Simultaneously
                  with counter-signature hereof by Yeda, XTL
                  shall provide Yeda with a bank guarantee from an Israeli bank,
                  in form
                  acceptable to Yeda, in order to secure XTL’s obligations under Sections
                  3.2.1 and 3.2.2 above. *****
                  of
                  the bank charges and commissions actually paid by XTL to the issuing
                  bank
                  in respect of the bank guarantee shall be reimbursed by Yeda to
                  XTL,
                  against proof of the amount paid by XTL, forthwith upon receipt
                  by Yeda of
                  the amount payable by XTL pursuant to Section 3.2.1
                  above.

              

      

      

      
        	4.	
                Entire
                  Agreement

              

      

      

      Except
        as
        set forth in this letter, all the terms of the R&L Agreement shall remain
        unchanged. The R&L Agreement, as amended hereunder, sets forth the entire
        understanding between Yeda and XTL regarding the R&L Agreement (except as
        supplemented by written instrument of even or subsequent date), and supersedes
        any other prior agreement or understanding, oral or written.

      

      Please
        indicate your acceptance of the terms of this letter by affixing your signature
        below.

      

      Very
        truly yours,

      XTL
        Biopharmaceuticals Ltd. 

      Martin
        Becker, Ph.D.

      President
        and CEO

      

      
        
           

        

        
          5

          
            

          

        

        
          
            *****
              Confidential material redacted and filed separately with the
              Commission.

          

        

         

      

      Agreed
        and Accepted:

      Yeda
        Research and Development Company Ltd.

      By:
        *****,
        President / Prof. *****,
        Chairman of the Board of Directors

      
        
           

        

        
          6

          
            

          

        

        
           

          
            *****
              Confidential material redacted and filed separately with the
              Commission.

          

        

      

      Research
        Plan

      

      
        	
                1.

              	
                Milestones
                  for Contract Research: Year 1

              

      

      

      
        	
                A.

              	
                *****

              

      

      

      
        	
                B.

              	
                *****

              

      

      

      
        	2.	
                Basic
                  Research: Year 1

              

      

      

      
        	
                A.

              	
                *****

              

      

      

      
        	
                B.

              	
                *****

              

      

      

      
        	
                C.

              	
                *****

              

      

      

      Note
        that
        confidential treatment has been requested and one (1) page of material has
        been
        omitted and filed separately with the Commission.

      
        
           

        

        
          7

          
            

          

        

        
           

          
            *****
              Confidential material redacted and filed separately with the
              Commission.

          

        

      

      

      Budget

      

      

      
        	
                1.

              	
                *****

              

      

      
        	 	
                a.

              	
                *****

              

      

      
        	 	
                b.

              	
                *****

              

      

      
        	 	
                c.

              	
                *****

              

      

      
        	 	
                d.

              	
                *****

              

      

      

      
        	2.	
                *****

              

      

      
        	 	
                a.

              	
                ***** 

              

      

      
        	 	
                b.

              	
                *****

              

      

      
        	 	
                c.

              	
                *****

              

      

      
        	 	
                d.

              	
                ***** 

              

      

      
        	 	
                e.

              	
                *****

              

      

      

      *****

      

      Note
        that
        confidential treatment has been requested and one (1) page of material has
        been
        omitted and filed separately with the Commission.

      

      
 

      
        
           

        

        
          8

          
            

          

        

        
           

          
            *****
              Confidential material redacted and filed separately with the
              Commission.

          

        

      

      Date:
        13
        February, 1996

      To:

      Yeda
        Research and Development Co (Yeda)

      

      Dear
        Sirs,

      

      Research
        and Development Agreement between XTL Biopharmaceuticals Ltd. ("XTL") and
        Neoprobe Corporation (“Neoprobe”)

      

      With
        reference to the Research and Development Agreement between XTL
        Biopharmaceuticals Ltd. and Neoprobe Corporation dated as of February 13,
        1996
        (“the Research Agreement”), XTL, hereby confirms, acknowledges and
        agrees:

      

      
        	
                (a)

              	
                that
                  any agreement by XTL to the amendment of the Research Agreement
                  (and/or
                  Exhibit B thereto) requires Yeda’s prior written
                  consent;

              

      

      
        	
                (b)

              	
                that
                  any agreement by XTL to the sublicensing or assignment of the Research
                  Agreement (and/or Exhibit B thereto) by Neoprobe requires Yeda’s prior
                  written consent;

              

      

      
        	
                (c)

              	
                that
                  any assignment by XTI. of its rights and obligations under the
                  Research
                  Agreement (and/or Exhibit B thereto) requires Yeda’s prior written
                  consent;

              

      

      
        	
                (d)

              	
                that
                  if XTL shall grant its agreement in either of the cases specified
                  in
                  subparagraphs (a) or (b) without first obtaining Yeda’s prior written
                  consent thereto or purport to make an assignment without first
                  obtaining
                  Yeda's prior written consent as required in subparagraph (c), XTL,
                  shall
                  be in material breach of the Research and License Agreement dated
                  as of
                  April 7, 1993 between Yeda and XTL (as amended) ("the
                  RLA”);

              

      

      
        	
                (e)

              	
                that
                  at Yeda’s request, XTL will exercise its right under Exhibit B of the
                  Research Agreement to inspect the books and accounts of
                  Neoprobe;

              

      

      
        	
                (f)

              	
                that
                  Yeda’s consent to the Research Agreement in no way derogates from the
                  provisions of the RLA, including - without limitation - Paragraph
                  7(c)(iv)
                  thereof, or from Yeda's rights and XTL's obligations
                  thereunder;

              

      

      
        	
                (g)

              	
                that,
                  at Yeda's request, XTL will exercise its legal rights under the
                  Research
                  Agreement (and/or Exhibit B thereto) against Neoprobe in the event
                  of a
                  breach of the Research Agreement (and/or Exhibit B thereto) by
                  Neoprobe
                  having an adverse effect for Yeda, including - without limitation
                  -
                  failure by Neoprobe to pay royalties due to XTL, under the Research
                  Agreement.

              

      

      

      Yours
        Faithfully,

      XTL
        Biopharmaceuticals Ltd.

      

      Agreed:

      Yeda
        Research and Development Co. Ltd.

      
        
           

        

        
          9

          
            

          

        

        
           

        

      

      February
        13, 1996

      

      To:

      Yeda
        Research and Development Co. Ltd. (Yeda)

      

      Dear
        Sirs,

      

      Research
        and Development Agreement between XTL Biopharmaceuticals Ltd
        (“XTL”) and Neoprobe Corporation (“Neoprobe”)

      

      With
        reference to the Research and Development Agreement between XTL
        Biopharmaceuticals Ltd. and Neoprobe
        Corporation dated as of February 13, 1996 (“the Research Agreement"). XTL hereby
        confirms, acknowledges and agrees:

      

      
        	
                (a)

              	
                that
                  any agreement by XTL to the amendment of the Research Agreement
                  (and/or
                  Exhibit B thereto) requires Yeda's prior written
                  consent;

              

      

      
        	
                (b)

              	
                that
                  any agreement by XTL the sublicensing or assignment of the Research
                  Agreement (and/or Exhibit B thereto) by
                  Neoprobe
                  requires Yeda’s prior written
                  consent;

              

      

      
        	
                (c)

              	
                that
                  any assignment by XTL of its rights and obligations under the Research
                  Agreement (and/or Exhibit B thereto) requires Yeda’s prior written
                  consent;

              

      

      
        	
                (d)

              	
                that
                  if XTL shall grant its agreement in either of the cases specified
                  in
                  subparagraphs (a) or (b) without first obtaining Yeda’s prior written
                  consent thereto or purport to make an assignment without first
                  obtaining
                  Yeda's prior written consent as required in subparagraph (c), XTL
                  shall be
                  in material breach of the Research and License Agreement dated
                  as of April
                  7, 1993 between Yeda and XTL (as amended) (“the
                  RLA”);

              

      

      
        	
                (e)

              	
                that
                  at Yeda’s request, XTL will exercise its right under Exhibit B of the
                  Research Agreement to inspect the books and accounts of
                  Neoprobe;

              

      

      
        	
                (f)

              	
                that
                  Yeda's consent to the Research Agreement in no way derogates from
                  the
                  provisions of the RLA, including - without limitation - Paragraph
                  7(c)(iv)
                  thereof, or from Yeda’s rights and XTL’s obligations
                  thereunder;

              

      

      
        	
                (g)

              	
                that,
                  at Yeda's request, XTL will exercise its legal rights
                  under
                  the Research Agreement (and/or Exhibit B thereto) against Neoprobe
                  in the
                  event of a breach of the Research Agreement (and/or Exhibit B thereto)
                  by
                  Neoprobe having an adverse effect for Yeda, including - without
                  limitation
                  - failure by Neoprobe to pay royalties due to XTL under the Research
                  Agreement.

              

      

      

      Yours
        Faithfully,

      XTL
        Biopharmaceuticals Ltd.

      

      Agreed:

      Yeda
        Research and Development Co. Ltd.

      
        
           

        

        
          10

          
            

          

        

        
           

        

      

      February
        13, 1996

      

      Yeda
        Research and Development Co. Ltd.

      P.O.
        Box
        95

      Rehovot
        76100

      Israel

      

      
        	Re:	
                “Research
                  and Development Agreement”

              

      

      Between
        XTL Biopharmaceuticals Ltd. and Neoprobe Corporation

      

      

      Gentlemen:

      

      In
        this
        subject agreement dated February 13, 1996, XTL granted an exclusive license
        to
        Neoprobe for the results of certain XTL research from XTL. This research
        will be
        based on certain XTL disease modeling and target agent technology. By this
        letter, Yeda Research and Development Company Limited (“Yeda”) and Neoprobe
        agree to the following:

      

      
        	 	
                a.

              	
                Yeda
                  acknowledges and consents to the Research and Development Agreement
                  between XTL and Neoprobe and to the Sublicense Agreement attached
                  therein;

              

      

      

      
        	 	
                b.

              	
                Neoprobe
                  confirms that Yeda is a third party beneficiary under the Research
                  and
                  Development Agreement as stated
                  therein;

              

      

      

      
        	 	
                c.

              	
                Yeda
                  agrees that, in the event that XTL defaults on the Research and
                  License
                  Agreement between XTL and Yeda dated as of April 7, 1993 (as amended)
                  (the
                  “RLA”), then, unless Yeda terminates the RLA, the exclusive grant
                  described in Article 6.1 of the Research and Development Agreement
                  (and
                  the rest of the Research and Development Agreement) and the Sublicense
                  Agreement attached thereto will not be affected. If the RLA is
                  terminated
                  for any reason, the Research and Development Agreement will terminate
                  automatically (except for Articles 2.1.3, 3, 4.1 (a) - (e) and
                  (f)
                  (provided that the grant under Article 6.1 still is in effect)
                  and 4.2, 5,
                  7 and 11 thereof, which shall survive), but the grant in Article
                  6.1 of
                  the Research and Development Agreement and the Sublicense Agreement
                  attached thereto shall be assumed (if still in force) by Yeda directly,
                  subject to Neoprobe’s continued performance under the Sublicense
                  Agreement, which obligations will, in such circumstances, be deemed
                  to be
                  owed directly to Yeda. For the guidance of all doubt, it is expressly
                  stated that except for the assumption of Article 6.1 and the Sublicense
                  Agreement as aforesaid, Yeda will not assume the research and development
                  of any other aspects of the Research and Development Agreement,
                  will not
                  under any circumstances be obliged to indemnify Neoprobe in respect
                  of any
                  claims, and will not be subject to Article 4 of the Sublicense
                  Agreement.

              

      

      

      
        	 	
                d.

              	
                Neoprobe
                  acknowledges that any agreement by XTL to any amendment to the
                  Research
                  and Development Agreement requires XTL to obtain Yeda’s prior written
                  consent, which consent will not be unreasonably withheld; and
                  

              

      

      

      
        	 	
                e.

              	
                Neoprobe
                  agrees that it will not make mention of the name of Yeda or the
                  Weizmann
                  Institute or any of the scientists thereof in any advertising,
                  sales,
                  literature, promotional material, other publications, private placement
                  memoranda, public

              

      

      
        
           

        

        
          11

          
            

          

        

        
           

          
            *****
              Confidential material redacted and filed separately with the
              Commission.

          

        

      

      offering
        registration statements and the like, unless the prior written approval of
        Yeda
        thereto has been obtained (such approval not to be unreasonably withheld)
        and
        except as required by law. Once an approval has been granted by Yeda to a
        certain form of words for use in a particular context, then the same form
        of
        words can be used again by Neoprobe in the same context, without further
        approval from Yeda.

      

      Please
        sign and date the attached copy of this letter and return it to me for my
        files.

      

      

      Neoprobe
        Corporation

      *****

      

      Agreed
        and Accepted:

      Yeda
        Research and Development Company Ltd.

      *****    *****

      *****    *****

      

      Agreed:

      XTL
        Biopharmaceuticals Ltd.

      Martin
        Becker, President

       

       

      
        
           

        

        
          12Confidential
        Treatment Requested. Confidential portions of this document have been redacted
        and separately filed with the Commission.

    

     

    

      SECOND
        EXTENSION AGREEMENT

      

      Between

      YEDA
        RESEARCH AND DEVELOPMENT CO. LTD. 

      of
        P.O.
        Box 95, Rehovot 76100, Israel 

      (hereinafter
        "Yeda") 

      and
        

      XTL
        BIOPHARMACEUTICALS LTD. 

      of
        Kiryat
        Weizmann PO Box 370 Rehovot 76100, Israel 

      (hereinafter
        "the Company")

      

      
        	WHEREAS	
                Yeda
                  and the Company have entered into a Research and Licence Agreement
                  dated
                  April 7, 1993 (hereinafter “the Main Agreement”) which was extended in an
                  Amendment of the Research and Licence Agreement on August 31, 1995
                  (hereinafter "the Amendment Agreement");
                  and

              

      

      

      
        	
                WHEREAS

              	
                Yeda
                  and the Company desire to further extend the Research Period and
                  agree to
                  the 1997 Budget and the 1997 Research Plan (as these terms are
                  hereinafter
                  defined) for said period;

              

      

      

      NOW
        THEREFORE IT IS AGREED BY THE PARTIES HERETO AS FOLLOWS:

      

      
        	
                1.
                  

              	
                Appendices

              

      

      

      The
        Appendices listed below which are attached hereto shall constitute an integral
        part hereof:

      Appendix
        1 - the 1997 Research Programme 

      Appendix
        2 - the 1997 Research Budget

      

      
        	
                2.
                  

              	
                Definitions

              

      

      

      
        	
                2.1.

              	
                “Yeda”
                  shall mean Yeda Research and Development Co. Ltd. of P.O. Box 95,
                  Rehovot
                  76100, Israel.

              

      

      

      
        	
                2.2.
                  

              	
                “The
                  Company” shall mean XTL Biopharmaceuticals Ltd., of Kiryat Weizmann, P.O.
                  Box 370, Rehovot 76100, Israel.

              

      

      

      
        	
                2.3.

              	
                “The
                  Main Agreement” shall mean the Research and Licence Agreement between Yeda
                  and the Company, dated April 7,
                  1993.

              

      

      

      
        	
                2.4.

              	
                “The
                  Amendment Agreement” shall mean the Amendment of Research and Licence
                  Agreement dated August 31, 1995.

              

      

      

      
        	
                2.5.
                  

              	
                “The
                  Research” shall mean the Research contemplated under the 1997 Research
                  Programme.

              

      

      

      
        	
                2.6.
                  

              	
                “The
                  1997 Research Programme” shall mean the research programme attached hereto
                  as Appendix 1.

              

      

      

      
        
           

        

        
           

          
            

          

        

        
          
            *****
              Confidential material redacted and filed separately with the
              Commission.

          

        

      

       

      
        	
                2.7.
                  

              	
                “The
                  1997 Research Period” shall mean the period commencing on September 1,
                  1996 and ending on August 31, 1997.

              

      

      

      
        	
                2.8.

              	
                “The
                  1997 Budget” shall mean the Budget for the Research as set forth in
                  Appendix 2 attached hereto.

              

      

      

      
        	
                3.

              	
                This
                  Second Extension Agreement shall be read together with the Amendment
                  Agreement and the Main Agreement and subject to the amendments
                  and
                  modifications contained herein, the provisions of said Amendment
                  Agreement
                  and Main Agreement shall remain unaltered and in full force and
                  effect.
                  Any words and phrases included in this Extension Agreement which
                  are
                  defined in the Main Agreement shall (unless the context otherwise
                  requires) have the same meaning attributed to such words or phrases
                  in the
                  Main Agreement.

              

      

      

      
        	
                4.

              	
                Performance
                  of the 1997 Research

              

      

      

      In
        consideration of the sums to be paid by the Company pursuant to Paragraph
        5
        below and subject to the execution of such payments, Yeda undertakes to procure
        the performance at the Institute of the 1997 Research Programme in whole
        or in
        part at the discretion of and under the supervision of the Scientist during
        the
        1997 Research Period.

      

      
        	
                5.

              	
                Funding
                  of the 1997 Research

              

      

      

      The
        Company shall provide Yeda with the total amount of ***** United States Dollars)
        to be used for financing the performance of the 1997 Research under Paragraph
        3
        above.

      

      The
        funds
        shall be paid in *****,
        each
        payable in advance on September 1, 1996 and then on March 1, 1997.

      

      IN
        WITNESS WHEREOF OF the parties have caused their respective representatives
        to
        execute this Agreement in two (2) counterparts, each of which shall be deemed
        as
        original.

      

      
        	
                for
                  XTL BIOPHARMACEUTICALS LTD.

                 

                Martin
                  Becker, President

                August
                  12, 1996

              	
                For
                  YEDA RESEARCH AND DEVELOPMENT CO. LTD.

                *****  *****

                *****  *****

                August
                  13, 1996

              

      

      

      I
        hereby
        confirm that I have read the above Agreement and I agree to act, to the best
        of
        my ability, in accordance with the terms and conditions of this Agreement
        insofar as it relates to me.

      

      *****

      August
        14, 1996

      
        
           

        

        
           

          
            

          

        

        
           

          
            *****
              Confidential material redacted and filed separately with the
              Commission.

          

        

      

      APPENDIX
        1

      *****

      

      *****

      

      
        	
                1.

              	
                *****

              

      

      

      
        	
                a.
                  

              	
                *****

              

      

      

      
        	
                b.

              	
                *****

              

      

      

      
        	
                c.

              	
                *****

              

      

      

      
        	
                2.

              	
                *****

              

      

      

      *****

      

      
        	
                3.

              	
                *****

              

      

      

      *****:   
        a.
        ***** 

                      
        b.
        *****

      

      
        	
                4.

              	
                *****

              

      

      

      *****

      

      *****

      

      *****

      

      Note
        that
        confidential treatment has been requested and one (1) page of material from
        this
        Appendix 1 has been omitted and filed separately with the
        Commission.

      
        
           

        

        
           

          
            

          

        

        
           

          
            *****
              Confidential material redacted and filed separately with the
              Commission.

          

        

      

      APPENDIX
        2

      *****

      

      *****

      

      

      *****

      

      Note
        that
        confidential treatment has been requested and one (1) page of material from
        this
        Appendix 2 has been omitted and filed separately with the
        Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}]]